Association between global leukocyte DNA methylation and cardiovascular risk in postmenopausal women

BMC Medical Genetics

Volumn 17, Issue 1, 2016, Pages

  Ramos, Ramon Bossardi ^a   Fabris, Vitor ^a   Lecke, Sheila Bunecker ^a,b   Maturana, Maria Augusta ^a,d,e   Spritzer, Poli Mara ^a,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^e UNIVERSIDADE DO VALE DO RIO DOS SINOS   (Brazil)

Author keywords

5 methylcytosine; Aging; Cardiovascular diseases; Epigenetics; Post menopause

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; DNA;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LEUKOCYTE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PATHOGENESIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; BLOOD; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK FACTOR;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOCYTES; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 84990852233     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-016-0335-x     Document Type: Article

References (50)

1. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-10.
2. Vaidya D, Becker DM, Bittner V, et al. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ. 2011;343:d5170.
3. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation. 2001;104:2815-9.
4. Koskinen J, Kahonen M, Viikari JS, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation. 2009;120:229-36.
5. Pappa T, Alevizaki M. Endogenous sex steroids and cardio- and cerebro-vascular disease in the postmenopausal period. Eur J Endocrinol. 2012;167:145-56.
6. Stamatelopoulos KS, Armeni E, Georgiopoulos G, et al. Recently postmenopausal women have the same prevalence of subclinical carotid atherosclerosis as age and traditional risk factor matched men. Atherosclerosis. 2012;221:508-13.
7. El Khoudary SR, Wildman RP, Matthews K, et al. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. Menopause. 2013;20:8-14.
8. Lambrinoudaki I, Armeni E, Georgiopoulos G, et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int J Cardiol. 2013;164:70-6.
9. Sayols-Baixeras S, Lluis-Ganella C, Lucas G, et al. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014;7:15-32.
10. Joseph PG, Pare G, Anand SS. Exploring gene-environment relationships in cardiovascular disease. Can J Cardiol. 2013;29:37-45.
11. Dawber TR, Meadors GF, Moore Jr FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279-81.
12. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53.
13. Whitfield JB. Genetic insights into cardiometabolic risk factors. Clin Biochem Rev. 2014;35:15-36.
14. Turgeon PJ, Sukumar AN, Marsden PA. Epigenetics of cardiovascular disease - a new "Beat" in coronary artery disease. Med Epigenet. 2014;2:37-52.
15. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747-53.
16. Ladd-Acosta C, Fallin MD. The role of epigenetics in genetic and environmental epidemiology. Epigenomics. 2016;8(2):271-83.
17. Waddington CH. Canalization of development and genetic assimilation of acquired characters. Nature. 1959;183:1654-5.
18. Heyn H, Moran S, Hernando-Herraez I, et al. DNA methylation contributes to natural human variation. Genome Res. 2013;23:1363-72.
19. Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23-38.
20. Whayne TF. Epigenetics in the development, modification, and prevention of cardiovascular disease. Mol Biol Rep. 2015;42:765-76.
21. Barlow DP, Bartolomei MS. Genomic imprinting in mammals. Cold Spring Harb Perspect Biol. 2014;6:a018382. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941233/pdf/cshperspect-EPI-a018382.pdf]
22. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3-29.
23. Bestor TH. The DNA, methyltransferases of mammals. Hum Mol Genet. 2000;9:2395-402.
24. Guerrero-Preston R. Global epigenetic screening technologies: a novel tool to address cancer health disparities in high-risk population groups. P R Health Sci J. 2008;27:350-6.
25. Guerrero-Preston R, Herbstman J, Goldman LR. Epigenomic biomonitors: global DNA hypomethylation as a biodosimeter of life-long environmental exposures. Epigenomics. 2011;3:1-5.
26. Soriano-Tarraga C, Jimenez-Conde J, Giralt-Steinhauer E, et al. Global DNA methylation of ischemic stroke subtypes. PLoS One. 2014;9:e96543.
27. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta. 2007;1775:138-62.
28. Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem. 2003;49:1292-6.
29. Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, et al. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrol Dial Transplant. 2008;23:2586-92.
30. Ordovas JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010;7:510-9.
31. Maturana MA, Franz RF, Metzdorf M, et al. Subclinical cardiovascular disease in postmenopausal women with low/medium cardiovascular risk by the Framingham risk score. Maturitas. 2015;81:311-6.
32. Framingham HS. Secondary. 2015. http://www.framinghamheartstudy.org/riskfunctions/cardiovascular-disease/10-year-risk.php.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
36. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol. 2009;54:2374-5.
37. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51:952-9.
38. Silva TR, Alves BC, Maturana MA, et al. Healthier dietary pattern and lower risk of metabolic syndrome in physically active postmenopausal women. J Am Coll Nutr. 2013;32:287-95.
39. Colpani V, Oppermann K, Spritzer PM. Association between habitual physical activity and lower cardiovascular risk in premenopausal, perimenopausal, and postmenopausal women: a population-based study. Menopause. 2013;20:525-31.
40. Smolarek I, Wyszko E, Barciszewska AM, et al. Global DNA methylation changes in blood of patients with essential hypertension. Med Sci Monit. 2010;16:CR149-55.
41. Baccarelli A, Wright R, Bollati V, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology. 2010;21:819-28.
42. Makar KW, Wilson CB. DNA methylation is a nonredundant repressor of the Th2 effector program. J Immunol. 2004;173:4402-6.
43. Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004;279:29147-54.
44. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315-22.
45. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A. 2000;97:5237-42.
46. Guo W, Chung WY, Qian M, et al. Characterizing the strand-specific distribution of non-CpG methylation in human pluripotent cells. Nucleic Acids Res. 2014;42:3009-16.
47. Tellez-Plaza M, Tang WY, Shang Y, et al. Association of global DNA methylation and global DNA hydroxymethylation with metals and other exposures in human blood DNA samples. Environ Health Perspect. 2014;122:946-54.
48. Guerrero-Preston R, Goldman LR, Brebi-Mieville P, et al. Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics. 2010;5:539-46.
49. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet. 2010;11:191-203.
50. Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet. 2012;13:705-19.